The use of naturally occurring viruses in the treatment of cancer is not new, and reports describing the administration of viruses to cancer patients date back more than fifty years. The advent of molecular biology and the arrival of biologics to the cancer therapy arena have now set the stage for a fresh look at the potential of these agents. These viruses have the potential to specifically target tumor cells, and insights into the molecular mechanisms of this selectivity are beginning to emerge.